Integrated Analysis of Slow Transit Constipation and Colorectal Cancer Reveals the Co-Pathogenic Targets and Their Potential Clinical Value

Slow transit constipation (STC) is a potential risk of the onset of colorectal cancer (CRC). Thus, the purpose of this work is to focus on the co-pathogenic targets between STC and CRC, meanwhile evaluating their prognostic value for CRC. The miRNA and mRNA data of STC and CRC were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. The prognostic signature was constructed based on hub genes, which identified using differential expression analysis and LASSO Cox regression analysis. The hub genes were validated employing multiple public databases. Enrichment analysis was employed to elucidate their functions. Survival analysis was performed using Kaplan-Meier method. Transcription factor binding sites were predicted and verified using FIMO and ChIP-seq database, respectively. We identified four common key differentially expressed miRNAs of STC and CRC, including hsa-miR-340, hsa-miR-30b, hsa-miR-20b, and hsa-miR-29c (p-value NOG + 0.074815408* PLD5 + 0.003499667* NOVA1 + 0.051762032*DTNA + 0.050495722* GPR26 + 0.045057094* TNFAIP8L3 + 0.097209257* SLC29A4+ (-0.246941474)* CCNJL + 0.039294168* TRABD2B. High-risk patients exhibited significantly poorer prognosis (p-value CCNJL, NOVA1, PLD5, and SLC29A4 were significantly down-regulated targets of hsa-miR-340 in the CRC samples (p-value CCNJL and SLC29A4, respectively. This study delved into common biomarkers between STC and CRC, and developed a reliable prognostic signature for CRC.